A new technique to study how myeloids become white blood cells

October 25, 2012

University of Illinois cell and developmental Biology professor Fei Wang and colleagues have created a new technique to study how myeloids, a type of blood stem cell, become the white blood cells important for immune system defense against infections and tissue damage. This approach offers new insights into the molecular mechanisms at work during myeloid differentiation, and may improve our ability to treat myeloid diseases like leukemia, the researchers report. Their findings appear in the journal Blood.

Myeloids are blood stem cells from bone marrow or the spinal cord that differentiate into common types of like and macrophages. Deficiencies in this differentiation process can cause leukemia.

Researchers in the field had previously studied myeloid differentiation by using cells taken directly from animals, or they transformed leukemia to their previous myeloid stem cell-like states. are hard to grow and manipulate genetically, however, and tumor cells still contain the that caused them to divide uncontrollably in the first place. The drawbacks of these systems prompted Wang to develop a better method for studying the mechanisms of myeloid differentiation.

Wang and his team began by turning mouse into myeloid progenitor cells. They then added a protein called Hoxb8 to these cells that had been shown previously to immortalize myeloid progenitor cells.


"This really simplified the whole system, so, number one, we didn't have to deal with animals or human bodies, and, number two, we immortalized these cells so that they can be easily handled in culture and maintain normal myeloid progenitor cell genetic information," Wang said. 



The researchers wanted to prove that their model is effective in helping them determine the important to myeloid differentiation, so they turned to a class of enzymes, called protein kinases, that are known to mediate processes like cell development, immune response, and cell differentiation. The researchers screened a variety of protein kinase inhibitors to find potential key regulators of myeloid differentiation.

A protein kinase inhibitor of a molecule called mTor, a master regulator of cell behavior, was found to interfere with myeloid differentiation, signifying that mTor is a key regulator of this process. Further experiments showed that this molecule is necessary for myeloid differentiation.

"This is the first evidence showing that this molecule plays a significant role in myeloid differentiation," Wang said.

This finding serves as a proof of principle that the new approach provides a powerful tool for future studies of normal and abnormal myeloid differentiation, Wang said.

"Using this system, we can introduce genetic manipulations that tell us something very important about how normal myeloid differentiation works, and what kind of molecular events in this process can go wrong, leading to diseases like leukemia," Wang said.

"People can use this as a platform for large-scale screening analysis for drugs that potentially can promote myeloid differentiation and can slow down or stop myeloid disease processes."

Explore further: A new target in acute myeloid leukemia

More information: Blood bloodjournal.hematologylibrary … 2-03-414979.abstract

Related Stories

A new target in acute myeloid leukemia

July 16, 2012
Acute myeloid leukemia, a common leukemia in adults, is characterized by aberrant proliferation of cancerous bone marrow cells. Activating mutations in a protein receptor known as FLT3 receptor are among the most prevalent ...

Study reveals origins of a cancer affecting the blood and bone marrow

May 12, 2011
A new study by the NYU Cancer Institute, an NCI-designated cancer center, sheds light on the origins of myeloid leukemia, a type of blood cancer that affects children and adults. The researchers discovered that novel mutations ...

Two-faced leukemia?

December 12, 2011
One kind of leukemia sometimes masquerades as another, according to a study published online this week in the Journal of Experimental Medicine.

Recommended for you

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

Testing the accuracy of FDA-approved and lab-developed cancer genetics tests

December 14, 2017
Cancer molecular testing can drive clinical decision making and help a clinician determine if a patient is a good candidate for a targeted therapeutic drug. Clinical tests for common cancer causing-mutations in the genes ...

Newest data links inflammation to chemo-brain

December 14, 2017
Inflammation in the blood plays a key role in "chemo-brain," according to a published pilot study that provides evidence for what scientists have long believed.

One in five young colon cancer patients have genetic link

December 13, 2017
As doctors grapple with increasing rates of colorectal cancers in young people, new research from the University of Michigan may offer some insight into how the disease developed and how to prevent further cancers. Researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.